Gastroparesis BBDC Clinical Diabetes Symposium 9/8/2018

Slides:



Advertisements
Similar presentations
Studio dello Svuotamento Gastrico
Advertisements

Anti-emetics and pro kinetics
Understanding Gastroparesis Enterra ® Therapy. 2 Anatomical Overview.
Enterra® Therapy Partnering for Gastric Health
Peptic ulcer disease.
Functional dyspepsia Ermias D. (MD). Diagnosis Functional, idiopathic, non ulcer Rome III criteria –Bothersome post prandial fullness –Early satiety –Epigastric.
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
Should we be evaluating patients in the hospital for gastropareis? If so, who?
GASTROPARESIS Arnold Wald, M.D., AGA-F
MOTILITY DISORDERS OF UPPER GI TRACT ACHALASIA GASTROPARESIS
Gastro-Esophageal Reflux Disease
Chapter 24 Agents Used to Treat Hyperacidity and Gastroesophageal Reflux Disease.
Advances in Gastroparesis Dmitry Oleynikov M.D, F.A.C.S Associate Professor of Surgery Joseph and Richard Still Faculty Fellow in Medicine Director of.
Diabetes in the 21 st Century 2010 Update. American Diabetes Association 2010 Guidelines – Diagnostic Criteria A1C > or = 6.5% is included as diagnostic.
Raneen Omary. Contents Definition Pathogenesis Epidemiology Acute Radiation Enteritis Chronic Radiation Enteritis Risk Factors Diagnosis DD Medical Management.
Gastroparesis Diagnosis and Treatment
Joint Meeting GISMAD-FISMAD DISTURBI DELLA MOTILITA’ G I NELLE PATOLOGIE SISTEMICHE DIABETE STRUTTURA COMPLESSA GASTROENTEROLOGIA, Cagliari STRUTTURA COMPLESSA.
Journal Club 2009 年 1 月 29 日(木) 8 : 20 ~ 8 : 50 B 棟 8 階カンファレンスルーム 薬剤部 TTSP 石井 英俊.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.
Gastroparesis Edmond Tai, Kar Yi Lim, Vivian Lin, Chan Park.
Clinical features of Upper GI origin More than 4 weeks duration Pain induced or worsened by food 40% of adults have in a life time Generally benign – promote.
Seminar in Palliative Care September 26 – October 02, 2010 Salzburg, Austria in Collaboration with.
Treatment Arvin M. Aningalan. Treatment Options Patient counseling and dietary alterations Diarrhea – Stool-bulking agents – Antidiarrheal Agents – Serotonin.
Pramlintide – An analog of amylin that overcomes the tendency of human amylin to: Aggregate, form insoluble particles Adhere to surfaces – Pharmacokinetic.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Drugs Used to Treat Gastroesophageal Reflux and Peptic Ulcer Diseases
Agents Used to Treat Hyperacidity and Gastroesophageal Reflux Disease
Chapter 25 Emetics and Antiemetics. Emetics p585 Agents that induce vomiting – Used in overdoses Example – Ipecac syrup Inappropriate use of emetics –
FUNCTIONAL DYSPEPSIA H Ali Djumhana.
 61 y o female with recent onset of nausea and vomiting  Roux-en-y gastric bypass 2 months ago due to an iatrogenic gastric perforation  History of.
1 III GASTRIC MOTILITY. 2 Major Function of Gastric Motility  To serve as a reservoir  To break food into small particles and mix food with gastric.
Approch to dyspepsia Vossoughinia H Associate professor of medicine Mashad university of medical sceinces.
Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.
Treating Gastroparesis Some Basics and a focus on acute pain control.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
Famotidine Is Inferior to Pantoprazole in Preventing Recurrence of Aspirin-Related Peptic Ulcers or Erosions FOOK–HONG NG, SIU–YIN WONG, KWOK–FAI LAM,
Treatment for Upper GI bleeding due to PUD. Goals Control upper GI bleeding Provide symptom relief Promote ulcer healing Prevent recurrence and other.
The Treatment of Diabetic Gastroparesis With Botulinum Toxin Injection of the Pylorus Brian E. Lacy, PHD, MD, Michael D. Crowell, PHD, Ann Schettler-Duncan,
Diabetic Gastroparesis
A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clerk 陳威任.
Gastroenterology and Nutrition in Chronic Kidney Disease Clinical Nephrology 5 th edition.
Difficult Case on T2Diabetes Management 2
FUNCTIONAL (NON-ULCER) DYSPEPSIA TUCOM Internal Medicine 4th class Dr
Fatimah Abdullah 6th year MS, KFU
Chapter 33 Therapy of Gastrointestinal Disorders: Peptic Ulcers, GERD, and Vomiting.
Jeopardy Final Jeopardy Antacids Antiemetics/ Emetics $100 $100 $100
Post-bariatric Surgery Hypoglycemia : A Descriptive Analysis
Antiemetic drugs.
Nuplazid™ - Pimavanserin
DYSPEPSIA Dr.Azam teimouri Gastroenterologist
TEGASEROD PROGRAM FUNCTIONAL DYSPEPSIA
Chronic Complications of Diabetes in Surgery
Focus on Irritable Bowel Syndrome (IBS)
Reflux esophagitis.
Drugs for Peptic Ulcer Disease
Drugs for the treatment of irritable bowel syndrome (IBS)
Drugs stimulating gastrointestinal motility
Management of the irritable bowel syndrome
Pramlintide Synthetic analog of the β-cell hormone amylin
GLP-1 Agonists and DPP-4 Inhibitors How do they work?
Other Gastrointestinal Drugs
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Volume 120, Issue 1, Pages (January 2001)
The Prevalence of Delayed Gastric Emptying in Cystic Fibrosis Lung Transplant Recipients Bridget Schuld, RD, LDN, CNSC; Katherine Young, MD; Erin M Lowery,
New Models of Care in Idiopathic Pulmonary Fibrosis
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.
Presentation transcript:

Gastroparesis BBDC Clinical Diabetes Symposium 9/8/2018 Joseph Auer, MD Assistant professor, gastroenterology, University of Kentucky

Resources and reviews Am J Gastroenterol 2013; 108:18–37; doi: 10.1038/ajg.2012.373; published online 13 November 2012 Diabetes Ther (2018) 9 (Suppl 1):S1–S42 https://doi.org/10.1007/s13300-018-0454-9

Disclosures I have no financial disclosures I will be mentioning some off-label use of medications during this activity.

Objectives Upon completion of this activity, participants will be able to: Select appropriate diagnostic testing for the evaluation of gastrointestinal comorbidities in patients with diabetes.

Diabetic autonomic Neuropathies Early glycemic control slows progression Gi associated neuropathies Esophageal dysmotility Gastroparesis enteropathies

Diabetic gastroparesis 20-50% of diabetics Type 1 dm (27-65%) … more common occurrence than in type 2 >10 years of type 2 dm …30% 34 years Mean age of onset More frequent in women Unclear why – perhaps hormonal

Diagnosis (syndrome) Symptoms Clinical symptoms in the absence of mechanical obstruction (peptic ulcer disease, gastric outlet obstruction, etc…) Documentation of delayed gastric emptying Degree of delay correlates poorly with severity of symptoms. Diagnosis (syndrome) Nausea, vomiting, early satiety, postprandial fullness, bloating, and upper abdominal pain. Functional dyspepsia , accelerated gastric emptying, PUD, H. Pylori, may present with the same symptoms. (ability to distinguish functional dyspepsia from idiopathic gastroparesis currently has limited value as treatments overlap but an important distinction for diabetic gastroparesis) Symptoms

Clinical Characteristics and distribution 36% idiopathic Significant proportion may be post- viral. 29% diabetic 13% postgastric surgery 7.5% Parkinson's disease 4.8% collagen vascular disorders 4.1% intestinal pseudoobstruction 6% miscellaneous causes Majority of cases occur in women for idiopathic as well as diabetic cases (unclear why). Soykan I, Sivri B, Saroseik I, et al.: Demography, clinical Characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 43:2398-2404 1998 PMID: 9824125

Differential Remember there are Other reasons to consider for gastroparesis even in the setting of diabetes Parkman, American Gastroenterological Association Technical Review on the Diagnosis and Treatment of Gastroparesis. GASTROENTEROLOGY 2004;127:1598

Gastric function / motility Turns out to be a very complicated process enteric neural plexus sympathetic and parasympathetic hormonal pacemaker cells – interstitial cells of cajal Damage to enteric nerves may disrupt normal mechanisms of motility / emptying. *Reservoir *Mixer *Empties

Gastric function / motility “The emptying of liquids is exponential. In contrast, the emptying of large solid particles only begins after sufficient grinding, resulting in a lag phase followed by the emptying of the viscous chyme mainly in a linear fashion” i.e. liquids empty much more easily Krishnasamy, S. & Abell, T.L. Diabetes Ther (2018) 9(Suppl 1): S9

Mechanisms of Diabetic gastroparesis Hormonal issues: * GLP-1(glucagon like peptide) secreted by the small intestine in response to nutrients slows gastric emptying * Amylin co-secreted with insulin (in response to glp-1) also slows gastric emptying

Krishnasamy, S. & Abell, T.L. Diabetes Ther (2018) 9(Suppl 1): S16

Diabetes and Gastroparesis Glycemic control is fundamental to treating gastroparesis. Hyperglycemia (at levels as low as 144 - 8 mmol / L) Delayed gastric emptying of both liquid and solids Variable dysrhythmias (gastric and intestinal) Tachygastrias , antral hypomotility Decreased effect of erythromycin and likely other motility drugs. Apoptosis of enteric neurons Loss of interstitial cells of Cajal (gastric pacing) Chaikomin, World J Gastroenterol 2006 September 21; 12(35): 611-5621

Medications and delayed gastric emptying Opioid analgesics Anticholinergic agents Tricyclic antidepressants Calcium channel blockers Progesterone Octreotide Proton pump inhibitors H2-receptor antagonists Interferon alfa L-dopa Fiber Exenatide Sucralfate Aluminum hydroxide antacids adrenergic receptor agonists Glucagon Calcitonin Dexfenfluramine Diphenhydramine Alcohol Tobacco/nicotine Tetrahydrocannabinol Camilleri, Clinical Guideline: Management of Gastroparesis, Am J Gastroenterol 2013; 108:18–37 Parkman, American Gastroenterological Association Technical Review on the Diagnosis and Treatment of Gastroparesis. GASTROENTEROLOGY 2004;127:1592–1622

Gastroparesis Evaluation Scintigraphic gastric emptying of solids is the standard for the evaluation of gastric emptying and the diagnosis of gastroparesis. The most reliable method and parameter for diagnosis of gastroparesis is gastric retention of solids at 4 h measured by scintigraphy. Studies of shorter duration or based on a liquid challenge result in decreased sensitivity in the diagnosis of gastroparesis. Patients with diabetes should have blood glucose measured before starting the gastric emptying test, and hyperglycemia treated with test started aft er blood glucose is < 275 mg / dl. EGD evaluation to exclude other processes. UGI series or other small bowel imaging to exclude mechanical obstruction.

Gastric scintigraphy Patient consumes standard radiolabeled meal within 10 min 99-m technetium sulfur colloid- labeled low-fat, egg-white meal (120 g) Optimize glycemic control (<275) and medications that slow emptying 2-3 days before procedure Imaging standing at 1, 2, 4 hours Delayed emptying > 60% at 2 hours or 10% retention at 4 hours

Other testing modalities (not standard practice) MRI with gadolinium Single photon emission CT Stable-isotope gastric emptying breath testing Wireless motility capsule electrogastrography

Diagnosis and Management Current evidence does not show benefit. Camilleri, Am J Gastroenterol. 2013 Jan;108(1):18-37

Treatment / Diet If possible, improve the underlying issue Glycemic control: difficult in the face of rapid and slowed emptying Medications Avoid narcotics for pain symptom Diet and education is the primary intervention Gastroparesis diet – multiple publications available. Small frequent meals (~6 meals per day) with liquids Low residue avoid fibrous food requiring gastric trituration Fibrous food promotes bezoar formation Avoid fatty foods – slows gastric emptying. < 40 gms per day Remember liquids require little gastric motility. May transition to blenderized diet when symptoms are more severe.

Forty-five type 1 or 2 patients with diabetes and gastroparesis and hemoglobin A1c >8% from the NIDDK Gastroparesis Consortium enrolled in a 24 week open-label pilot prospective study of CSII plus CGM Conclusion: CSII plus CGM appeared to be safe with minimal risks of hypoglycemic events and associated improvements in glycemic control, gastroparesis symptoms, quality-of-life, and meal tolerance in patients with poorly controlled diabetes and gastroparesis. This study supports the safety, feasibility, and potential benefits of improving glycemic control in diabetic gastroparesis. April 2018

Prokinetic Medications Metoclopramide (FDA approved for gastroparesis) Erythromycin Domperidone not available in US without investigational new drug clearance from FDA Like Reglan without central effects

Metoclopramide Maybe it was the metoclopramide Mechanism: Dopamine receptor antagonist central/peripheral, 5-HT3 antagonist, 5-HT4 agonist. Prokinetic and antiemetic properties. Side effects CNS side effects in 20–30% Tardive dyskinesia is real and potentially irreversible. FDA box warning Parkinson type syndrome Dystonic reaction Risk of tardive dyskinesia Hyperprolactinemia May prolong qt Dosing: 5- 20 mg qid (use lowest dose possible) Maybe it was the metoclopramide

Erythromycin Mechanism: Motilin receptor agonist. No antiemetic effect. Side effects Nausea, vomiting, abdominal pain Qtc may be prolonged and Ekg should be obtained at baseline and during tx Tachyphylaxis limits long term use Dosing: 125mg to 250 mg bid to tid. (use in lowest effective dose)

Domepridone Mechanism: Peripheral D2 antagonist – increases antral contractions, decreased fundal relaxation, improves antroduodenal coordination. Side effects Prolonged QT – need ekg and follow periodically Do not use with qtc > 470 ms in men and > 450 ms in women Dosing: 10- 30 mg po QID. Not available in US without IND. Sounds similar but totally different

Nausea Antiemetics Phenothiazines Serotonin 5-ht3 antagonists promethazine Serotonin 5-ht3 antagonists Ondansetron Antihistamines Diphenhydramine TCA Nortriptyline, mirtazapine Avoid amitriptyline due to more prominent anticholinergic effects

Medication Algorithim Camilleri, Clinical Guideline: Management of Gastroparesis, Am J Gastroenterol 2013; 32

Gastric Electrical Stimulation GES may be considered for compassionate treatment in patients with refractory symptoms, particularly nausea and vomiting. Symptom severity and gastric emptying have been shown to improve in patients with diabetic gastroparesis, but not in patients with idiopathic or postsurgical gastroparesis. Camilleri, Clinical Guideline: Management of Gastroparesis, Am J Gastroenterol 2013; 108:18–37

Other options Gastrectomy Surgical pyloroplasty gastrojejunostomy Cam Acupuncture Ginger

Camilleri, Clinical Guideline: Management of Gastroparesis, Am J Gastroenterol 2013; 108:24

Krishnasamy, S. & Abell, T. L. Diabetes Ther (2018) 9(Suppl 1): 1